ICIs primarily target negative immune checkpoint molecules, including cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed death 1 (PD-1), and programmed death-ligand 1 (PD-L1), which are involved in strengthening the immune response and postponing tumor advancement [113]. Here, CTLA4 is linked to neoplasm.